Primaquine diphosphate
Based on 7 publication(s) in Google Scholar
Primaquine diphosphate is a potent antimalaria agent and a potent gametocytocide in falciparum malaria. Primaquine diphosphate prevents relapse in vivax and ovale malaria.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.39%
- CAS No.: 63-45-6
- Formule: C15H27N3O9P2
- Masse moléculaire:455.34
-
Stockage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-17589A
ChloroquineAntimalarial Agent -
HY-17001
Flupirtine MaleatePotassium Channel Opener -
HY-N0134
Tanshinone IPhospholipase Inhibitor -
HY-17589
Chloroquine phosphateAntimalarial Agent -
HY-13555
β-LapachoneAutophagy Inducer -
HY-B0586
MethylcobalaminVitamin B12 -
HY-12651R
Primaquine diphosphate (Standard)Antimalarial Agent -
HY-N0402
ArtemetherParasite Inhibitor -
HY-A0059
NifuratelBroad-Spectrum Antibiotic -
HY-17036
Naphthoquine phosphateAntimalarial And Antiviral Agent -
HY-12784A
Cycloguanil hydrochlorideDihydrofolate Reductase Inhibitor -
HY-B2138
EthopabateAntiparasitic Agent
Publications Citing Use of MedChemExpress (MCE) Primaquine diphosphate
More- Adv Sci (Weinh). 2025 Jan;12(1):e2410285. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- ACS Omega. 2024 Feb 28;9(10):11870-11882. [Abstract]
- iScience. 2026 Jun 30;29(7):116415.
- Adv Ther (Weinh). 05 October 2021.
- Biomed Pharmacother. 2026 Feb:195:118973. [Abstract]
- Ann Transl Med. 2021 Feb;9(3):194. [Abstract]
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
Cell Imaging/Staining
-
Cell Imaging/Staining
-
WB
Voir tous les produits spécifiques à Isoform Parasite
More
Activité biologique
Description
IC50 & Target
|
Plasmodium |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
5 μM
Compound: PQ diphosphate
|
Cytotoxicity against human A2780 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A2780 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29407988] |
| CAPAN-1 | IC50 |
14.24 μM
Compound: PQ diphosphate
|
Cytotoxicity against human Capan1 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human Capan1 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29407988] |
| HCT-116 | IC50 |
13.99 μM
Compound: PQ
|
Antiproliferative activity against human HCT116 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells measured after 72 hrs by MTT assay
|
[PMID: 31431364] |
| HCT-116 | IC50 |
44.22 μM
Compound: PQ diphosphate
|
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29407988] |
| HEK293 | IC50 |
10.96 μM
Compound: PQ
|
Antiproliferative activity against human HEK293 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human HEK293 cells measured after 72 hrs by MTT assay
|
[PMID: 31431364] |
| HepG2 | IC50 |
>100 μM
Compound: 92125578
|
HARVARD: Cytotoxicity in HepG2 cell line
HARVARD: Cytotoxicity in HepG2 cell line
|
[PMID: 22586124] |
| HepG2 | IC50 |
7.4 μM
Compound: 92125578
|
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells
|
[PMID: 22586124] |
| HL-60 | IC50 |
11.36 μM
Compound: PQ diphosphate
|
Cytotoxicity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29407988] |
| K562 | IC50 |
12.04 μM
Compound: PQ diphosphate
|
Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29407988] |
| L6 | IC50 |
27.1 μg/mL
Compound: PQ diphsophate
|
Cytotoxicity against rat L6 cells after 70 hrs by Alamar Blue-based assay
Cytotoxicity against rat L6 cells after 70 hrs by Alamar Blue-based assay
|
[PMID: 29220797] |
| L6 | IC50 |
59.5 μM
Compound: PQ diphosphate
|
Cytotoxicity against rat L6 cells assessed as reduction in cell viability after 70 hrs by Alamar blue assay
Cytotoxicity against rat L6 cells assessed as reduction in cell viability after 70 hrs by Alamar blue assay
|
[PMID: 29407988] |
| MCF7 | IC50 |
5 μM
Compound: PQ diphosphate
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29407988] |
| MCF7 | IC50 |
8.73 μM
Compound: PQ
|
Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay
|
[PMID: 31431364] |
| NCI-H460 | IC50 |
10 μM
Compound: PQ diphosphate
|
Cytotoxicity against human NCI-H460 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29407988] |
| NCI-H460 | IC50 |
19.84 μM
Compound: PQ
|
Antiproliferative activity against human H460 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human H460 cells measured after 72 hrs by MTT assay
|
[PMID: 31431364] |
| SW-620 | IC50 |
14 μM
Compound: PQ diphosphate
|
Cytotoxicity against human SW620 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human SW620 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29407988] |
In Vitro
Primaquine diphosphate significantly decreases the cell proliferation of live breast cancer cells, and shows no inhibitory effect on the proliferation of MCF-7 (ER+) and MDA-MB-453 (HER2+) cells. Primaquine diphosphate inhibits the growth, migration, and colony formation of breast cancer cells in vitro[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231, HCC1937 cells, MCF-7, and MDA-MB-453 cells
-
Concentration:5 μM, 10 μM, 20 μM, 40 μM, 80 μM, 100 μM, 120 μM, and 150 μM
-
Incubation Time:24 hours
-
Result:Decreases breast cancer cell viability.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male 6-week-old C57BL/6 albino mice with sporozoite inoculation[2]
-
Dosage:5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, and 25 mg/kg
-
Administration:p.o; daily; for 3 days
-
Result:No blood stage parasitaemia was observed.
Chemical Information
-
CAS No. 63-45-6
-
Appearance Solid
-
Masse moléculaire 455.34
-
Formule C15H27N3O9P2
-
Color Orange to reddish brown
-
SMILES
CC(NC1=C2N=CC=CC2=CC(OC)=C1)CCCN.O=P(O)(O)O.O=P(O)(O)O
-
Synonyms
Primaquine phosphate; Primaquine bisphosphate
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Network Medicine-Based Strategy Identifies Maprotiline as a Repurposable Drug by Inhibiting PD-L1 Expression via Targeting SPOP in Cancer. [Abstract]2025 Jan;12(1):e2410285. PMID: 39499771 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
ACS Omega
Identification of New Modulators and Inhibitors of Palmitoyl-Protein Thioesterase 1 for CLN1 Batten Disease and Cancer. [Abstract]2024 Feb 28;9(10):11870-11882. PMID: 38496939 -
-
-
Biomed Pharmacother
As a novel ferroptosis inhibitor, primaquine alleviates I/R-induced retinal neuron death via increasing GSTA1 activity. [Abstract]2026 Feb:195:118973. PMID: 41529513
Primaquine diphosphate purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2026 Feb:195:118973. [Abstract]
Primaquine (5, 10,20, 40, 80, 100 μM; 24 h) showed no cytotoxic effects at concentrations up to 80.0 μM, while toxicity was observed at 100 μM in R28 cells.
Primaquine diphosphate purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2026 Feb:195:118973. [Abstract]
Primaquine (5, 10, 20 μM; 24 h) significantly decreased OGD/R-induced PI-positive cells in R28 cells.
Primaquine diphosphate purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2026 Feb:195:118973. [Abstract]
Primaquine (10 μM; 6 h; Erastin; 2.0 μM; 12 h) protect R28 cells against Erastin-induced cell death in R28 cells.
Primaquine diphosphate purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2026 Feb:195:118973. [Abstract]
Primaquine (10 μM; 6 h; RSL3; 2.0 μM; 3 h) inhibited RSL3-induced accumulation of intracellular ROS and mitochondrial damage in R28 cells.
Primaquine diphosphate purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2026 Feb:195:118973. [Abstract]
Primaquine (10 μM; 6 h) increased OGD/R-induced the levels decrease of both SLC7A11 and GPX4 proteins in R28 cells.
Primaquine diphosphate purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2026 Feb:195:118973. [Abstract]
rimaquine (200 μM; 1.5 μL; injected into the intravitreal space; befroe the establishment of aHIOP 24 h) mitigated these aHIOP-induced changes, resulting in improved cellular definition, better tissue organization, and increased cell number in the GCL by about 15 % compared to the aHIOP group alone.
Primaquine diphosphate purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2026 Feb:195:118973. [Abstract]
Primaquine (200 μM; 1.5 μL; injected into the intravitreal space; befroe the establishment of aHIOP 24 h) reduced SLC7A11 and GPX4 protein expression in retinal tissues of aHIOP mice.
-
Ann Transl Med
Integrative identification of the pathogenic role of a novel G6PD missense mutation c.697G>C. [Abstract]2021 Feb;9(3):194. PMID: 33708821
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (219.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 25 mg/mL (54.90 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.57 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.57 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (109.81 mM); Clear solution; Need ultrasonic
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Pureté et documentation
-
Fiche technique (279 KB)
-
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Ashley EA, et al. Primaquine: the risks and the benefits. Malar J. 2014 Nov 3;13:418. [Content Brief]
[2]. Qigui Li, et al. Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections. Malar J. 2014 Apr 14:13:141. [Content Brief]
[3]. Ji-Hyang Kim, et al. Primaquine Inhibits the Endosomal Trafficking and Nuclear Localization of EGFR and Induces the Apoptosis of Breast Cancer Cells by Nuclear EGFR/Stat3-Mediated c-Myc Downregulation. Int J Mol Sci. 2021 Nov 30;22(23):12961. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.1962 mL | 10.9808 mL | 21.9616 mL | 54.9040 mL |
| 5 mM | 0.4392 mL | 2.1962 mL | 4.3923 mL | 10.9808 mL | |
| 10 mM | 0.2196 mL | 1.0981 mL | 2.1962 mL | 5.4904 mL | |
| 15 mM | 0.1464 mL | 0.7321 mL | 1.4641 mL | 3.6603 mL | |
| 20 mM | 0.1098 mL | 0.5490 mL | 1.0981 mL | 2.7452 mL | |
| 25 mM | 0.0878 mL | 0.4392 mL | 0.8785 mL | 2.1962 mL | |
| 30 mM | 0.0732 mL | 0.3660 mL | 0.7321 mL | 1.8301 mL | |
| 40 mM | 0.0549 mL | 0.2745 mL | 0.5490 mL | 1.3726 mL | |
| 50 mM | 0.0439 mL | 0.2196 mL | 0.4392 mL | 1.0981 mL | |
| DMSO | 60 mM | 0.0366 mL | 0.1830 mL | 0.3660 mL | 0.9151 mL |
| 80 mM | 0.0275 mL | 0.1373 mL | 0.2745 mL | 0.6863 mL | |
| 100 mM | 0.0220 mL | 0.1098 mL | 0.2196 mL | 0.5490 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Primaquine diphosphate Related Classifications
HY-12651 Related Classifications
Powered by Bioz